用8-α-氨基麦角灵对帕金森症进行初始治疗。

Initial treatment of parkinsonism with 8-alpha-amino-ergoline.

作者信息

Teräväinen H, Huttunen J, Hietanen M

出版信息

Neurology. 1985 Jan;35(1):83-7. doi: 10.1212/wnl.35.1.83.

DOI:10.1212/wnl.35.1.83

Abstract

We treated 12 patients with Parkinson's disease with an 8-alpha-amino-ergoline derivative, CU 32-085. The daily dosage was increased slowly to 7 mg over 9 weeks, held constant for 8 weeks, then replaced by placebo for 4 weeks. We found statistically significant benefit over placebo or pretreatment disability. The effect was seen at daily dosages of 3 mg or more. Its magnitude was dose related. There was no further improvement on prolonged treatment with 7 mg daily. Side effects were mild and did not require interruption of treatment.

摘要

我们用一种8-α-氨基麦角灵衍生物CU 32 - 085治疗了12例帕金森病患者。每日剂量在9周内缓慢增加至7毫克，维持8周不变，然后用安慰剂替代4周。我们发现与安慰剂或治疗前的残疾状况相比，有统计学上的显著益处。每日剂量3毫克及以上时可见效果。其程度与剂量相关。每日7毫克的长期治疗未见进一步改善。副作用轻微，无需中断治疗。